Artiva Biotherapeutics (ARTV)

• Market cap: $551M
• 1 day: -2.68%
• 5 days: 12.7%
• 1 month: 18.88%
• 3 months: -9.98%
• 6 months: 201.34%
• Year to date: 166.43%
• 1 year: 326.89%
• 5 years: -6.08%
• 10 years: -6.08%
• Sector: Healthcare
• Industry: Biotechnology

About: Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).

Employees: 106